Trial software firm Medable has partnered with Masimo to integrate wearable monitoring devices into its drug study offering.
The accord – financial terms of which were not provided – has already seen Medable use a blood oxygen monitor developed by Masimo in eight drug industry-sponsored trials in lung and breast cancer.
Medable cited the accuracy of Mesimo’s technology – particularly its ability to take variables like patient motion or low perfusion into account – as the basis for the partnership.
Musaddiq Khan, Medable’s Vice President of Digital Outcomes and TA Strategy, said “Masimo’s SET pulse oximetry is sensitive enough to capture key vitals on the very ill like cancer patients, plus it works on all skin tones, all ages, and is easy to use.”
He added: “The Masimo team is terrific, and we look forward to long-term, collaboration so we can leverage more of their novel wearables to improve data quality and enable patients to participate in trials with less burden.”
Medable claims to have deployed its software-as-a-service platform in more than 300 decentralized and hybrid clinical trials in 60 countries, serving more than one million patients and research participants globally. According to the firm, customers have achieved 200 percent faster enrolment and 50 percent cost reductions.
Collaboration strategy
Partnership has been central to Medable’s strategy in recent years. In 2022, for example, it teamed with US pharmacy chain CVS to “expand clinical trial access and engagement for patients” through the latter organization’s chain of MinuteClinic businesses.
And last year Medable teamed-up with the Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard (MRCT Center) to develop a toolkit for Institutional Review Boards (IRBs)/Ethics Committees (ECs).
More recently, the firm signed an accord with the Duke University Department of Population Health Sciences’ Bioethics and Stakeholder (BASE) Lab In a project focused on electronic informed consent in clinical trials.
DepositPhotos/masha_tace